首页 | 本学科首页   官方微博 | 高级检索  
     

艾拉莫德联合甲氨蝶呤治疗类风湿性关节炎临床研究
引用本文:莫守崎,许百洁,李依蓝,薛晓倩,王震汕,李奕琏. 艾拉莫德联合甲氨蝶呤治疗类风湿性关节炎临床研究[J]. 现代药物与临床, 2018, 41(7): 1288-1291
作者姓名:莫守崎  许百洁  李依蓝  薛晓倩  王震汕  李奕琏
作者单位:揭阳市人民医院(中山大学附属揭阳医院)风湿免疫科, 广东 揭阳 522000,揭阳市人民医院(中山大学附属揭阳医院)风湿免疫科, 广东 揭阳 522000,揭阳市人民医院(中山大学附属揭阳医院)体检中心, 广东 揭阳 522000,揭阳市人民医院(中山大学附属揭阳医院)风湿免疫科, 广东 揭阳 522000,揭阳市人民医院(中山大学附属揭阳医院)放射科, 广东 揭阳 522000,揭阳市人民医院(中山大学附属揭阳医院)风湿免疫科, 广东 揭阳 522000
基金项目:揭阳市科技计划项目(2015B01003)
摘    要:目的 研究艾拉莫德联合甲氨蝶呤治疗类风湿性关节炎临床效果。方法 选择2015年1月-2017年11月在揭阳市人民医院进行诊治的60例类风湿性关节炎患者,随机分为两组。对照组口服甲氨蝶呤治疗,每次10 mg,每天1次;观察组联合口服艾拉莫德治疗,每次25 mg,每天2次。两组均治疗3个月。比较两组的临床治疗效果,并比较两组治疗前后的血清C反应蛋白、类风湿因子、抗环瓜氨酸肽抗体和红细胞沉降率,以及白介素-6、淋巴细胞绝对值、免疫球蛋白G。结果 观察组的有效率90.00%高于对照组70.00%,差异有统计学意义(P<0.05)。治疗后两组的血清C反应蛋白、类风湿因子、抗环瓜氨酸肽抗体和红细胞沉降率均明显降低,同组治疗前后比较差异有统计学意义(P<0.05);且观察组明显低于对照组,组间差异有统计学意义(P<0.05)。治疗后两组的淋巴细胞绝对值、免疫球蛋白G、白介素-6均明显降低,同组治疗前后比较差异有统计学意义(P<0.05);且观察组明显低于对照组,组间差异有统计学意义(P<0.05)。两组的不良反应率相比无明显差异。结论 艾拉莫德联合甲氨蝶呤治疗类风湿性关节炎临床效果显著,是一种安全有效的治疗方案。

关 键 词:甲氨蝶呤  艾拉莫德  类风湿性关节炎  临床效果
收稿时间:2018-01-09

Clinical analysis of methotrexate combined with iguratimod in the treatment of rheumatoid arthritis
MO Shouqi,XU Baijie,LI Yilan,XUE Xiaoqian,WANG Canshan and LI Yilian. Clinical analysis of methotrexate combined with iguratimod in the treatment of rheumatoid arthritis[J]. Drugs & Clinic, 2018, 41(7): 1288-1291
Authors:MO Shouqi  XU Baijie  LI Yilan  XUE Xiaoqian  WANG Canshan  LI Yilian
Affiliation:Rheumatology Department of Jieyang People''s Hospital(Jieyang Affiliated Hospital of Sun Yat-sen University), Jieyang 522000, China,Rheumatology Department of Jieyang People''s Hospital(Jieyang Affiliated Hospital of Sun Yat-sen University), Jieyang 522000, China,Health Examination Center of Jieyang People''s Hospital(Jieyang Affiliated Hospital of Sun Yat-sen University), Jieyang 522000, China,Rheumatology Department of Jieyang People''s Hospital(Jieyang Affiliated Hospital of Sun Yat-sen University), Jieyang 522000, China,Radiology Department of Jieyang People''s Hospital(Jieyang Affiliated Hospital of Sun Yat-sen University), Jieyang 522000, China and Rheumatology Department of Jieyang People''s Hospital(Jieyang Affiliated Hospital of Sun Yat-sen University), Jieyang 522000, China
Abstract:Objective To investigate the clinical effect ofmethotrexate combined with iguratimod in the treatment of rheumatoid arthritis.Methods Selected 60 cases of patients with rheumatoid arthritis who were treated in our hospital from January 2015 to November 2017, divided into two groups randomly. The control group was treated with methotrexate, 10 mg each time, 1 times a day. The observation group was treated with oral iguratimod, 25 mg each time, 2 times a day. The clinical therapeutic effect of two groups were compared, and compared the serum C reactive protein, rheumatoid factor and anti-cyclic citrullinated peptide antibody and erythrocyte sedimentation rate, interleukin -6, LYMPH, immunoglobulin G.Results After treatment, the effective rate of the observation group was 90.00% (27/30), which was higher than 70.00% of the control group (21/30) (P < 0.05); after treatment, serum C reactive protein,, rheumatoid factor, anti-cyclic citrullinated peptide antibody and erythrocyte sedimentation rate of the two groups were significantly lower (P < 0.05), and the observation group was more obvious (P < 0.05); the levels of interleukin-6, immunoglobulin G, LYMPH in the two groups were significantly lower (P < 0.05), and the observation group was more obvious (P < 0.05). There was no significant difference in the adverse reaction rate between the two groups.Conclusion Methotrexate combined with iguratimod in the treatment of rheumatoid arthritis clinical effect is significant, is a safe and effective treatment.
Keywords:methotrexate  iguratimod  rheumatoid arthritis  clinical effect
点击此处可从《现代药物与临床》浏览原始摘要信息
点击此处可从《现代药物与临床》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号